MolPharm xPharm- The Comprehensive Pharmacology Reference

Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
 QUICK SEARCH:   [advanced]


     


This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Mhaouty-Kodja, S.
Right arrow Articles by Cotecchia, S.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Mhaouty-Kodja, S.
Right arrow Articles by Cotecchia, S.

Vol. 55, Issue 2, 339-347, February 1999

Constitutively Active Alpha-1b Adrenergic Receptor Mutants Display Different Phosphorylation and Internalization Features

Sakina Mhaouty-Kodja, Larry S. Barak, Alexander Scheer, Liliane Abuin, Dario Diviani, Marc G. Caron, and Susanna Cotecchia

Institut de Pharmacologie et de Toxicologie, Faculté de Médecine, 1005 Lausanne, Switzerland (S.M-K., A.S., L.A., D.D., S.C.); and Howard Hughes Medical Institute, Duke University Medical Center, Durham, North Carolina (L.S.B., M.G.C.)

We compared the phosphorylation and internalization properties of constitutively active alpha-1b adrenergic receptor (AR) mutants carrying mutations in two distant receptor domains, i.e., at A293 in the distal part of the third intracellular loop and at D142 of the DRY motif lying at the end of the third transmembrane domain. For the A293E and A293I mutants the levels of agonist-independent phosphorylation were 150% and 50% higher than those of the wild-type alpha-1b AR, respectively. On the other hand, for the constitutively active D142A and D142T mutants, the basal levels of phosphorylation were similar to those of the wild-type alpha-1b AR and did not appear to be further stimulated by epinephrine. Overexpression of the guanyl nucleotide binding regulatory protein-coupled receptor kinase GRK2 further increases the basal phosphorylation of the A293E mutant, but not that of D142A mutant. Both the wild-type alpha-1b AR and the A293E mutant could undergo beta -arrestin-mediated internalization. The epinephrine-induced internalization of the constitutively active A293E mutant was significantly higher than that of the wild-type alpha-1b AR. In contrast, the D142A mutant was impaired in its ability to interact with beta -arrestin and to undergo agonist-induced internalization. Interestingly, a double mutant A293E/D142A retained very high constitutive activity and regulatory properties of both the A293E and D142A receptors. These findings demonstrate that two constitutively activating mutations occurring in distant receptor domains of the alpha-1b AR have divergent effects on the regulatory properties of the receptor.


Copyright © 1999 by The American Society for Pharmacology and Experimental Therapeutics



This article has been cited by other articles:


Home page
Proc. Natl. Acad. Sci. USAHome page
N. Makita, J. Sato, K. Manaka, Y. Shoji, A. Oishi, M. Hashimoto, T. Fujita, and T. Iiri
An acquired hypocalciuric hypercalcemia autoantibody induces allosteric transition among active human Ca-sensing receptor conformations
PNAS, March 27, 2007; 104(13): 5443 - 5448.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
F. Novi, L. Stanasila, F. Giorgi, G. U. Corsini, S. Cotecchia, and R. Maggio
Paired Activation of Two Components within Muscarinic M3 Receptor Dimers Is Required for Recruitment of {beta}-Arrestin-1 to the Plasma Membrane
J. Biol. Chem., May 20, 2005; 280(20): 19768 - 19776.
[Abstract] [Full Text] [PDF]


Home page
J Mol EndocrinolHome page
I. Langer, C. Langlet, and P. Robberecht
Effect of inactivating mutations on phosphorylation and internalization of the human VPAC2 receptor
J. Mol. Endocrinol., April 1, 2005; 34(2): 405 - 414.
[Abstract] [Full Text] [PDF]


Home page
Cardiovasc ResHome page
L. Barki-Harrington, C. Perrino, and H. A Rockman
Network integration of the adrenergic system in cardiac hypertrophy
Cardiovasc Res, August 15, 2004; 63(3): 391 - 402.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
L. Stanasila, J.-B. Perez, H. Vogel, and S. Cotecchia
Oligomerization of the {alpha}1a- and {alpha}1b-Adrenergic Receptor Subtypes: POTENTIAL IMPLICATIONS IN RECEPTOR INTERNALIZATION
J. Biol. Chem., October 10, 2003; 278(41): 40239 - 40251.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
D. Diviani, A.-L. Lattion, L. Abuin, O. Staub, and S. Cotecchia
The Adaptor Complex 2 Directly Interacts with the {alpha}1b-Adrenergic Receptor and Plays a Role in Receptor Endocytosis
J. Biol. Chem., May 23, 2003; 278(21): 19331 - 19340.
[Abstract] [Full Text] [PDF]


Home page
J. Pharmacol. Exp. Ther.Home page
J.-G. Li, F. Zhang, X.-L. Jin, and L.-Y. Liu-Chen
Differential Regulation of the Human kappa Opioid Receptor by Agonists: Etorphine and Levorphanol Reduced Dynorphin A- and U50,488H-Induced Internalization and Phosphorylation
J. Pharmacol. Exp. Ther., May 1, 2003; 305(2): 531 - 540.
[Abstract] [Full Text] [PDF]


Home page
J. Pharmacol. Exp. Ther.Home page
M. J. Gerdin, M. I. Masana, D. Ren, R. J. Miller, and M. L. Dubocovich
Short-Term Exposure to Melatonin Differentially Affects the Functional Sensitivity and Trafficking of the hMT1 and hMT2 Melatonin Receptors
J. Pharmacol. Exp. Ther., March 1, 2003; 304(3): 931 - 939.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
K. Tumova, R. M. Iwasiow, and M. Tiberi
Insight into the Mechanism of Dopamine D1-like Receptor Activation. EVIDENCE FOR A MOLECULAR INTERPLAY BETWEEN THE THIRD EXTRACELLULAR LOOP AND THE CYTOPLASMIC TAIL
J. Biol. Chem., February 28, 2003; 278(10): 8146 - 8153.
[Abstract] [Full Text] [PDF]


Home page
J. Pharmacol. Exp. Ther.Home page
J. J. Carrillo, P. A. Stevens, and G. Milligan
Measurement of Agonist-Dependent and -Independent Signal Initiation of alpha 1b-Adrenoceptor Mutants by Direct Analysis of Guanine Nucleotide Exchange on the G Protein Galpha 11
J. Pharmacol. Exp. Ther., September 1, 2002; 302(3): 1080 - 1088.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
M. C. Levin, S. Marullo, O. Muntaner, B. Andersson, and Y. Magnusson
The Myocardium-protective Gly-49 Variant of the beta 1-Adrenergic Receptor Exhibits Constitutive Activity and Increased Desensitization and Down-regulation
J. Biol. Chem., August 16, 2002; 277(34): 30429 - 30435.
[Abstract] [Full Text] [PDF]


Home page
Mol. Pharmacol.Home page
D. Chalothorn, D. F. McCune, S. E. Edelmann, M. L. Garcia-Cazarin, G. Tsujimoto, and M. T. Piascik
Differences in the Cellular Localization and Agonist-Mediated Internalization Properties of the alpha 1-Adrenoceptor Subtypes
Mol. Pharmacol., May 1, 2002; 61(5): 1008 - 1016.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
S. Miserey-Lenkei, C. Parnot, S. Bardin, P. Corvol, and E. Clauser
Constitutive Internalization of Constitutively Active Angiotensin II AT1A Receptor Mutants Is Blocked by Inverse Agonists
J. Biol. Chem., February 15, 2002; 277(8): 5891 - 5901.
[Abstract] [Full Text] [PDF]


Home page
J. Pharmacol. Exp. Ther.Home page
J. Wang, L. Wang, J. L. Anderson, N. A. Schulte, and M. L. Toews
Regulatory Properties of alpha 1B-Adrenergic Receptors Defective in Coupling to Phosphoinositide Hydrolysis
J. Pharmacol. Exp. Ther., January 1, 2002; 300(1): 134 - 141.
[Abstract] [Full Text] [PDF]


Home page
Mol. Pharmacol.Home page
J. Li, C. Chen, P. Huang, and L.-Y. Liu-Chen
Inverse Agonist Up-Regulates the Constitutively Active D3.49(164)Q Mutant of the Rat {micro}-Opioid Receptor by Stabilizing the Structure and Blocking Constitutive Internalization and Down-Regulation
Mol. Pharmacol., November 1, 2001; 60(5): 1064 - 1075.
[Abstract] [Full Text]


Home page
Mol. Pharmacol.Home page
J. P. McLaughlin and C. Chavkin
Tyrosine Phosphorylation of the {micro}-Opioid Receptor Regulates Agonist Intrinsic Efficacy
Mol. Pharmacol., June 1, 2001; 59(6): 1360 - 1368.
[Abstract] [Full Text]


Home page
EndocrinologyHome page
V. Simon, S. Mhaouty-Kodja, C. Legrand, and J. Cohen-Tannoudji
Concomitant Increase of G Protein-Coupled Receptor Kinase Activity and Uncoupling of {beta}-Adrenergic Receptors in Rat Myometrium at Parturition
Endocrinology, May 1, 2001; 142(5): 1899 - 1905.
[Abstract] [Full Text]


Home page
EndocrinologyHome page
P. H. Carter, B. D. Petroni, R. C. Gensure, E. Schipani, J. T. Potts Jr., and T. J. Gardella
Selective and Nonselective Inverse Agonists for Constitutively Active Type-1 Parathyroid Hormone Receptors: Evidence for Altered Receptor Conformations
Endocrinology, April 1, 2001; 142(4): 1534 - 1545.
[Abstract] [Full Text]


Home page
Mol. Pharmacol.Home page
M. Waelbroeck
Activation of Guanosine 5'-[{gamma}-35S]thio-triphosphate Binding through M1 Muscarinic Receptors in Transfected Chinese Hamster Ovary Cell Membranes: 2. Testing the "Two-States" Model of Receptor Activation
Mol. Pharmacol., April 1, 2001; 59(4): 886 - 893.
[Abstract] [Full Text]


Home page
FASEB J.Home page
T. KENAKIN
Inverse, protean, and ligand-selective agonism: matters of receptor conformation
FASEB J, March 1, 2001; 15(3): 598 - 611.
[Abstract] [Full Text] [PDF]


Home page
Mol. Endocrinol.Home page
S. L. Ferrari and A. Bisello
Cellular Distribution of Constitutively Active Mutant Parathyroid Hormone (PTH)/PTH-Related Protein Receptors and Regulation of Cyclic Adenosine 3',5'-Monophosphate Signaling by {beta}-Arrestin2
Mol. Endocrinol., January 1, 2001; 15(1): 149 - 163.
[Abstract] [Full Text]


Home page
Proc. Natl. Acad. Sci. USAHome page
L. S. Barak, R. H. Oakley, S. A. Laporte, and M. G. Caron
Constitutive arrestin-mediated desensitization of a human vasopressin receptor mutant associated with nephrogenic diabetes insipidus
PNAS, December 22, 2000; (2000) 11303698.
[Abstract] [Full Text]


Home page
Mol. Endocrinol.Home page
L. Min and M. Ascoli
Effect of Activating and Inactivating Mutations on the Phosphorylation and Trafficking of the Human Lutropin/Choriogonadotropin Receptor
Mol. Endocrinol., November 1, 2000; 14(11): 1797 - 1810.
[Abstract] [Full Text]


Home page
GeneticsHome page
N. S. Olesnicky, A. J. Brown, Y. Honda, S. L. Dyos, S. J. Dowell, and L. A. Casselton
Self-Compatible B Mutants in Coprinus With Altered Pheromone-Receptor Specificities
Genetics, November 1, 2000; 156(3): 1025 - 1033.
[Abstract] [Full Text]


Home page
Mol. Pharmacol.Home page
P. A. Stevens, N. Bevan, S. Rees, and G. Milligan
Resolution of Inverse Agonist-Induced Up-Regulation from Constitutive Activity of Mutants of the alpha 1b-Adrenoceptor
Mol. Pharmacol., August 1, 2000; 58(2): 438 - 448.
[Abstract] [Full Text]


Home page
Mol. Pharmacol.Home page
D. F. McCune, S. E. Edelmann, J. R. Olges, G. R. Post, B. A. Waldrop, D. J. J. Waugh, D. M. Perez, and M. T. Piascik
Regulation of the Cellular Localization and Signaling Properties of the alpha 1B- and alpha 1D-Adrenoceptors by Agonists and Inverse Agonists
Mol. Pharmacol., April 1, 2000; 57(4): 659 - 666.
[Abstract] [Full Text]


Home page
Endocr. Rev.Home page
U. Gether
Uncovering Molecular Mechanisms Involved in Activation of G Protein-Coupled Receptors
Endocr. Rev., February 1, 2000; 21(1): 90 - 113.
[Abstract] [Full Text]


Home page
Mol. Pharmacol.Home page
A. Scheer, T. Costa, F. Fanelli, P. G. De Benedetti, S. Mhaouty-Kodja, L. Abuin, M. Nenniger-Tosato, and S. Cotecchia
Mutational Analysis of the Highly Conserved Arginine within the Glu/Asp-Arg-Tyr Motif of the alpha 1b-Adrenergic Receptor: Effects on Receptor Isomerization and Activation
Mol. Pharmacol., February 1, 2000; 57(2): 219 - 231.
[Abstract] [Full Text]


Home page
J. Biol. Chem.Home page
W. G. Thomas, H. Qian, C.-S. Chang, and S. Karnik
Agonist-induced Phosphorylation of the Angiotensin II (AT1A) Receptor Requires Generation of a Conformation That Is Distinct from the Inositol Phosphate-signaling State
J. Biol. Chem., January 28, 2000; 275(4): 2893 - 2900.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
J.-P. Vilardaga, M. Frank, C. Krasel, C. Dees, R. A. Nissenson, and M. J. Lohse
Differential Conformational Requirements for Activation of G Proteins and the Regulatory Proteins Arrestin and G Protein-coupled Receptor Kinase in the G Protein-coupled Receptor for Parathyroid Hormone (PTH)/PTH-related Protein
J. Biol. Chem., August 31, 2001; 276(36): 33435 - 33443.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
S. R. Hawtin, A. B. Tobin, S. Patel, and M. Wheatley
Palmitoylation of the Vasopressin V1a Receptor Reveals Different Conformational Requirements for Signaling, Agonist-induced Receptor Phosphorylation, and Sequestration
J. Biol. Chem., October 5, 2001; 276(41): 38139 - 38146.
[Abstract] [Full Text] [PDF]


Home page
Proc. Natl. Acad. Sci. USAHome page
L. S. Barak, R. H. Oakley, S. A. Laporte, and M. G. Caron
Constitutive arrestin-mediated desensitization of a human vasopressin receptor mutant associated with nephrogenic diabetes insipidus
PNAS, January 2, 2001; 98(1): 93 - 98.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Physiol. Heart Circ. Physiol.Home page
K. Ziani, R. Gisbert, M. A. Noguera, M. D. Ivorra, and P. D'Ocon
Modulatory role of a constitutively active population of alpha 1D-adrenoceptors in conductance arteries
Am J Physiol Heart Circ Physiol, February 1, 2002; 282(2): H475 - H481.
[Abstract] [Full Text] [PDF]


Home page
Mol. Biol. CellHome page
C. Blanpain, J.-M. Vanderwinden, J. Cihak, V. Wittamer, E. Le Poul, H. Issafras, M. Stangassinger, G. Vassart, S. Marullo, D. Schlondorff, et al.
Multiple Active States and Oligomerization of CCR5 Revealed by Functional Properties of Monoclonal Antibodies
Mol. Biol. Cell, February 1, 2002; 13(2): 723 - 737.
[Abstract] [Full Text] [PDF]




Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
All ASPET Journals Molecular Pharmacology Pharmacological Reviews
 Molecular Interventions Drug Metabolism and Disposition

Copyright © 1999 by the American Society for Pharmacology and Experimental Therapeutics